SeaLife Pharma GmbH is proud to announce that it has partnered in the EU FP7 funded project named Macumba - Marine Microorganisms: Cultivation Methods for Improving their Biotechnological Applications, with a total funding of 12 Mio € and 23 partners from 11 nations.
The core objective of the MaCuMBA project is to uncover the untapped biodiversity of uncultured marine microbes using an array of new cultivation-dependent strategies. The project goals are to improve the isolation rate and growth efficiency of new marine microorganisms from conventional and extreme habitats by applying innovative methods and using automated high-throughput procedures.
For SeaLife, this presents a great opportunity to work with a highly experienced consortium of marine microbiologists and engineers and provides an opportunity to fully utilize its marine microbial platform and pre-clinical screening knowledge for identification of novel lead candidates.
With this second EU funded project, SeaLife aims to strengthen its position within Europe as a partner for drug discovery and development and also to benefit from accessing an international pipeline of drug discovery activities.
see more on www.macumbaproject.eu